$VMNT
Vemanti Group, Inc.

2021 Q4 Form 10-Q Financial Statement

#000147793221007877 Filed on November 05, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q4
Revenue $36.91K $37.11K
YoY Change -6.06%
Cost Of Revenue $5.990K $5.804K
YoY Change -35.6%
Gross Profit $30.92K $31.31K
YoY Change 2.67%
Gross Profit Margin 83.77% 84.36%
Selling, General & Admin $563.9K $607.2K
YoY Change
% of Gross Profit 1823.84% 1939.47%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $180.00 $190.00
YoY Change
% of Gross Profit 0.58% 0.61%
Operating Expenses $563.9K $607.2K
YoY Change 2103.94%
Operating Profit -$533.0K -$575.9K
YoY Change -19661.79%
Interest Expense -$3.890K $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $0.00 -$1.068K
YoY Change -81.61%
Pretax Income -$533.0K -$577.0K
YoY Change 20038.46%
Income Tax $30.00 $820.00
% Of Pretax Income
Net Earnings -$533.0K -$577.8K
YoY Change 7256.6%
Net Earnings / Revenue -1444.16% -1556.87%
Basic Earnings Per Share $0.00
Diluted Earnings Per Share -$0.01 $0.00
COMMON SHARES
Basic Shares Outstanding 70.30M shares 69.84M shares
Diluted Shares Outstanding 69.84M shares

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $302.0K $433.9K
YoY Change
Cash & Equivalents $295.9K $427.8K $243.5K
Short-Term Investments $6.110K $6.110K
Other Short-Term Assets $6.107K $0.00
YoY Change
Inventory
Prepaid Expenses $0.00
Receivables $4.415K $1.109K $1.224K
Other Receivables $25.14K $25.14K
Total Short-Term Assets $331.6K $460.2K $269.2K
YoY Change 23.17%
LONG-TERM ASSETS
Property, Plant & Equipment $632.00 $817.00 $1.373K
YoY Change -53.97%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $296.4K $296.4K $298.1K
YoY Change -0.55%
Total Long-Term Assets $297.0K $297.2K $299.4K
YoY Change -0.8%
TOTAL ASSETS
Total Short-Term Assets $331.6K $460.2K $269.2K
Total Long-Term Assets $297.0K $297.2K $299.4K
Total Assets $628.6K $757.4K $568.6K
YoY Change 10.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.502K $14.34K $1.077K
YoY Change 318.01%
Accrued Expenses $427.3K $420.3K $0.00
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $125.0K $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $556.8K $434.6K $1.690K
YoY Change 32846.45%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $125.0K
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $125.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $556.8K $434.6K $1.690K
Total Long-Term Liabilities $0.00 $125.0K
Total Liabilities $556.8K $559.6K $1.690K
YoY Change 32846.45%
SHAREHOLDERS EQUITY
Retained Earnings -$3.284M -$2.751M -$1.659M
YoY Change 97.96%
Common Stock $7.040K $6.991K $6.898K
YoY Change 2.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $71.84K $197.7K $567.0K
YoY Change
Total Liabilities & Shareholders Equity $628.6K $757.4K $568.6K
YoY Change 10.55%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q4
OPERATING ACTIVITIES
Net Income -$533.0K -$577.8K
YoY Change 7256.6%
Depreciation, Depletion And Amortization $180.00 $190.00
YoY Change
Cash From Operating Activities -$131.9K -$149.2K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 125.0K
YoY Change
NET CHANGE
Cash From Operating Activities -131.9K -149.2K
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 0.000 125.0K
Net Change In Cash -131.9K -24.19K
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$131.9K -$149.2K
Capital Expenditures $0.00 $0.00
Free Cash Flow -$131.9K -$149.2K
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Assets Current
AssetsCurrent
269216 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
817 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1373 USD
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
296405 USD
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
70304086 shares
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
427805 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
243494 USD
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1109 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1224 USD
CY2021Q3 us-gaap Due From Officers Or Stockholders Current
DueFromOfficersOrStockholdersCurrent
25142 USD
CY2020Q4 us-gaap Due From Officers Or Stockholders Current
DueFromOfficersOrStockholdersCurrent
24498 USD
CY2021Q3 us-gaap Other Assets Current
OtherAssetsCurrent
6107 USD
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
0 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
460163 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
298056 USD
CY2021Q3 us-gaap Assets
Assets
757385 USD
CY2020Q4 us-gaap Assets
Assets
568645 USD
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
14340 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1077 USD
CY2021Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0 USD
CY2020Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
613 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
420300 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
0 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
434640 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1690 USD
CY2021Q3 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
125000 USD
CY2020Q4 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
0 USD
CY2021Q3 us-gaap Liabilities
Liabilities
559640 USD
CY2020Q4 us-gaap Liabilities
Liabilities
1690 USD
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
40000000 shares
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
4000 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
4000 USD
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
69914086 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
68984086 shares
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
6991 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
6898 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-60713 USD
CY2020Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2937802 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2215020 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2751048 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1658963 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
197745 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
566955 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1177954 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
157043 USD
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
607207 USD
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
27551 USD
us-gaap Operating Expenses
OperatingExpenses
1177954 USD
us-gaap Operating Expenses
OperatingExpenses
157043 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-575899 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
2944 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-1083171 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
757385 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
568645 USD
CY2021Q3 us-gaap Revenues
Revenues
37112 USD
CY2020Q3 us-gaap Revenues
Revenues
39507 USD
us-gaap Revenues
Revenues
111039 USD
us-gaap Revenues
Revenues
126816 USD
CY2021Q3 us-gaap Cost Of Revenue
CostOfRevenue
5804 USD
CY2020Q3 us-gaap Cost Of Revenue
CostOfRevenue
9012 USD
us-gaap Cost Of Revenue
CostOfRevenue
16256 USD
us-gaap Cost Of Revenue
CostOfRevenue
30486 USD
CY2021Q3 us-gaap Gross Profit
GrossProfit
31308 USD
CY2020Q3 us-gaap Gross Profit
GrossProfit
30495 USD
us-gaap Gross Profit
GrossProfit
94783 USD
us-gaap Gross Profit
GrossProfit
96330 USD
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
607207 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27551 USD
CY2020Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2130 USD
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
12626 USD
CY2021Q3 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 USD
CY2020Q3 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
5086 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1750 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
5086 USD
CY2021Q3 us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
0 USD
CY2020Q3 us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
-13025 USD
us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
-1651 USD
us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
-5176 USD
CY2021Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
1068 USD
CY2021Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
0 USD
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
3893 USD
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1068 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5809 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7294 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
12536 USD
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-576967 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2865 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1090465 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-48177 USD
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
820 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4989 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1620 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-17 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-577787 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-7854 USD
us-gaap Net Income Loss
NetIncomeLoss
-1092085 USD
us-gaap Net Income Loss
NetIncomeLoss
-48160 USD
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69844086 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
68984086 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69513976 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
68984086 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69844086 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
68984086 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69513976 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
68984086 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
566955 USD
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
265000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
761988 USD
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
150000 USD
CY2021Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
151500 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-444331 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
619157 USD
CY2021Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
156375 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-577787 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
197745 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
643831 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
3145 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
612905 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-7854 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
605051 USD
us-gaap Net Income Loss
NetIncomeLoss
-48160 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
556 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
555 USD
us-gaap Professional Fees
ProfessionalFees
307875 USD
us-gaap Professional Fees
ProfessionalFees
0 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
1651 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
5176 USD
us-gaap Asset Impairment Charges
AssetImpairmentCharges
3893 USD
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
115 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1786 USD
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-644 USD
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-5364 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
13263 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-500 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
420300 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1484 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-613 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-345689 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-48595 USD
us-gaap Proceeds From Collection Of Loans Receivable
ProceedsFromCollectionOfLoansReceivable
0 USD
us-gaap Proceeds From Collection Of Loans Receivable
ProceedsFromCollectionOfLoansReceivable
200000 USD
us-gaap Payments To Acquire Assets Investing Activities
PaymentsToAcquireAssetsInvestingActivities
10000 USD
us-gaap Payments To Acquire Assets Investing Activities
PaymentsToAcquireAssetsInvestingActivities
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
200000 USD
us-gaap Proceeds From Contributions From Affiliates
ProceedsFromContributionsFromAffiliates
125000 USD
us-gaap Proceeds From Contributions From Affiliates
ProceedsFromContributionsFromAffiliates
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
415000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
540000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
184311 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
151405 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
243494 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
118806 USD
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
427805 USD
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
270211 USD
us-gaap Interest Paid Net
InterestPaidNet
0 USD
us-gaap Interest Paid Net
InterestPaidNet
0 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1620 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
800 USD
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Certain amounts reported in the prior year financial statements have been reclassified to conform to the current year’s presentation.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of condensed consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates made by management include, among others, revenue recognition, recoverability of accounts receivable, investments and deferred income taxes. Actual results could differ from those estimates. It is possible that accounting estimates and assumptions may be material to the Company due to the levels of subjectivity and judgment involved.</p>
CY2020Q4 us-gaap Intangible Assets Current
IntangibleAssetsCurrent
0 USD
vmnt Purchase Of Crypto Currencies
PurchaseOfCryptoCurrencies
10000 USD
CY2020 vmnt Purchase Of Crypto Currencies
PurchaseOfCryptoCurrencies
0 USD
us-gaap Asset Impairment Charges
AssetImpairmentCharges
3893 USD
CY2020 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2021Q3 us-gaap Intangible Assets Current
IntangibleAssetsCurrent
6107 USD
CY2020Q4 us-gaap Intangible Assets Current
IntangibleAssetsCurrent
0 USD
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
40000000 shares
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
24498 USD
CY2021Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
25142 USD

Files In Submission

Name View Source Status
0001477932-21-007877-index-headers.html Edgar Link pending
0001477932-21-007877-index.html Edgar Link pending
0001477932-21-007877.txt Edgar Link pending
0001477932-21-007877-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vemanti_10q.htm Edgar Link pending
vemanti_10q_htm.xml Edgar Link completed
vemanti_ex311.htm Edgar Link pending
vemanti_ex312.htm Edgar Link pending
vemanti_ex321.htm Edgar Link pending
vemanti_ex322.htm Edgar Link pending
vmnt-20210930.xsd Edgar Link pending
vmnt-20210930_cal.xml Edgar Link unprocessable
vmnt-20210930_def.xml Edgar Link unprocessable
vmnt-20210930_lab.xml Edgar Link unprocessable
vmnt-20210930_pre.xml Edgar Link unprocessable